睿智醫藥(300149.SZ)：凱惠藥業的上訴被予以駁回
格隆匯 3 月 16日丨睿智醫藥(300149.SZ)公佈，公司全資孫公司凱惠藥業因被認定涉嫌構成污染環境的單位犯罪被江陰市人民檢察院起訴，相關情況詳見公司分別於2018年8月28日、2018年10月8日在中國證監會指定的創業板信息披露網站披露的《全資孫公司凱惠藥業(上海)有限公司涉嫌污染環境案的公吿》、《全資孫公司凱惠藥業(上海)有限公司涉嫌污染環境案的進展公吿》。
2019年11月19日，凱惠藥業簽收了江蘇省江陰市人民法院的《刑事判決書》((2018)蘇0281刑初2073號)，關於凱惠藥業的判決內容為：凱惠藥業犯污染環境罪，判處罰金人民幣80萬元(罰金於本判決發生法律效力第二日起十日內一次性繳納)。公司認為案件實際情況與判決內容存在差異，凱惠藥業委託代理律師，依據國家法律、法規和相關事實提交了上訴狀。相關情況詳見公司於2019年11月21日披露的《全資孫公司凱惠藥業(上海)有限公司涉嫌污染環境案的進展公吿》。
近日，江蘇省南京市中級人民法院出具了《刑事裁定書》((2020)蘇01刑終66號)，對凱惠藥業的上訴予以駁回，維持原判，公司將不再申請再審。
上述訴訟判決結果對公司本期及期後利潤不會造成影響。凱惠藥業系公司重大資產重組標的企業上海睿智化學研究有限公司的子公司，涉嫌污染環境案發生於資產重組交割日前，根據重組交易協議，交易對方上海睿昀企業管理中心(有限合夥)、China Gateway Life Science (Holdings) Limited 及上海睿釗企業管理中心(有限合夥)將對因此次訴訟給公司造成的損失承擔連帶賠償責任。
綜上，公司認為上述訴訟事件所產生的生態環境影響已消除，凱惠藥業被起訴至今，正常經營，沒有出現因本訴訟導致停工停產情況，其對公司生產經營、財務狀況及償債能力無重大不利影響，未觸發《深圳證券交易所創業板股票上市規則》10.5.1條規定的相關重大違法強制退市的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
